STK25 and metabolic dysfunction-associated steatotic liver disease: We have previously demonstrated that Stk25–/– mice and mice treated with Mst3-targeting ASO are protected from the development of diet-induced MASLD as evidenced by decreased hepatic steatosis, lobular inflammation, and nutritional fibrosis [14, 21–23].